Organ-Specific Dosimetry Following Radiopharmaceutical Therapy for Metastatic Prostate Cancer

Introduction Radiopharmaceutical Therapy (RPT) uses radioactive agents to target cancer at the cellular level Lu-177 targeting prostate-specific membrane antigen (PSMA), known as 177Lu- PSMA-617, can be used to treat metastatic, castration-resistant prostate cancer (mCRPC) 177Lu-PSMA-617 treatments use a standard dose and treatment regimen for all patients Patients exhibit different side effects and tumor response during treatment

Publication Details

Journal: The Medicine Forum
Published: 2024-08-30
Primary Topic: Scientific Computing and Data Management
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Organ-Specific Dosimetry Following Radiopharmaceutical Therapy for Metastatic Prostate Cancer

Aug 30, 2024

The Medicine Forum

Scientific Computing and Data Management

article

Organ-Specific Dosimetry Following Radiopharmaceutical Therapy for Metastatic Prostate Cancer

August 30, 2024article en

Abstract

The Medicine Forum

Good health and well-being

Openalex Percentile: Top 24%

Scientific Computing and Data Management

Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Organ-Specific Dosimetry Following Radiopharmaceutical Therapy for Metastatic Prostate Cancer · The Medicine Forum (2024) | TGRS Research Map | TGRS